Leqvio Sales Still Lag But Novartis Is Playing The Long Game
Brings In Just $22m In Q2
The twice-yearly cholesterol injectable approved in Europe 18 months ago is still not making any commercial headway but Novartis's CEO Vas Narasimhan has stressed that the groundwork for access to and education about Leqvio is being firmly laid.
